References
1. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA
Covid-19 Vaccine. N. Engl. J. Med. 383 , 2603–2615
(2020).
2. Baden, L. R. et al. Efficacy and Safety of the mRNA-1273
SARS-CoV-2 Vaccine. N. Engl. J. Med. 384 , 403–416
(2021).
3. Levin, E. G. et al. Waning Immune Humoral Response to BNT162b2
Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 385 ,
e84 (2021).
4. Goldberg, Y. et al. Protection and Waning of Natural and
Hybrid Immunity to SARS-CoV-2. N. Engl. J. Med. 386 ,
2201–2212 (2022).
5. Bar-On, Y. M. et al. Protection against Covid-19 by BNT162b2
Booster across Age Groups. N. Engl. J. Med. 385 ,
2421–2430 (2021).
6. Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled
by prototype pathogen preparedness. Nature 586 , 567–571
(2020).
7. Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and
immune escape. Nat. Rev. Microbiol. 19 , 409–424 (2021).
8. Uraki, R. et al. Characterization and antiviral susceptibility
of SARS-CoV-2 Omicron/BA.2. Nature (2022)
doi:10.1038/s41586-022-04856-1.
9. Abu-Raddad, L. J. et al. Effect of mRNA Vaccine Boosters
against SARS-CoV-2 Omicron Infection in Qatar. N. Engl. J. Med.386 , 1804–1816 (2022).
10. Barda, N. et al. Effectiveness of a third dose of the
BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel:
an observational study. Lancet Lond. Engl. 398 ,
2093–2100 (2021).
11. Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine
boosters induce neutralizing immunity against SARS-CoV-2 Omicron
variant. Cell 185 , 457-466.e4 (2022).
12. Chu, L. et al. Immune response to SARS-CoV-2 after a booster
of mRNA-1273: an open-label phase 2 trial. Nat. Med. 28 ,
1042–1049 (2022).
13. Kuhlmann, C. et al. Breakthrough infections with SARS-CoV-2
omicron despite mRNA vaccine booster dose. Lancet Lond. Engl.399 , 625–626 (2022).
14. Casian, J. G. et al. Saliva-Based ELISAs for Effective
SARS-CoV-2 Antibody Monitoring in Vaccinated Individuals. Front.
Immunol. 12 , 701411 (2021).
15. MacMullan, M. A. et al. Detection of SARS-CoV-2 Antibodies in
Oral Fluid Obtained Using a Rapid Collection Device. J. Clin.
Microbiol. 59 , e02510-20 (2021).
16. Thomas, S. N. et al. Ultrasensitive detection of salivary
SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19
vaccine-induced immunity. Sci. Rep. 12 , 8890 (2022).
17. Mades, A. et al. Detection of persistent SARS-CoV-2 IgG
antibodies in oral mucosal fluid and upper respiratory tract specimens
following COVID-19 mRNA vaccination. Sci. Rep. 11 , 24448
(2021).
18. Johnson, A. G. et al. COVID-19 Incidence and Death Rates
Among Unvaccinated and Fully Vaccinated Adults with and Without Booster
Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S.
Jurisdictions, April 4-December 25, 2021. MMWR Morb. Mortal. Wkly.
Rep. 71 , 132–138 (2022).
19. Andrews, N. et al. Covid-19 Vaccine Effectiveness against the
Omicron (B.1.1.529) Variant. N. Engl. J. Med. 386 ,
1532–1546 (2022).
20. Chalkias, S. et al. A Bivalent Omicron-Containing Booster
Vaccine against Covid-19. N. Engl. J. Med. 387 ,
1279–1291 (2022).